New evidence confirms patients with severe psoriasis are at a higher risk for heart disease

In the largest study to date exploring the relationship between severe psoriasis and coronary microvascular dysfunction, researchers have found further evidence that patients with severe psoriasis are at higher cardiovascular risk. The results opens in new tab/window are published in the Journal of Investigative Dermatology opens in new tab/window, published by Elsevier.

Psoriasis is a chronic systemic immune-mediated inflammatory disease that affects 1-3% of the global population. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate coronary microcirculation. Investigators uncovered a high prevalence of coronary microvascular dysfunction in more than 30% of asymptomatic patients within the study population.

Lead investigator Stefano Piaserico, MD, PhD, Dermatology Unit, Department of Medicine, University of Padova, explained, "Previous studies have shown that patients with severe psoriasis have an increased cardiovascular morbidity and mortality. However, there has been limited research on the specific mechanisms underlying this increased risk, particularly regarding coronary microvascular dysfunction. We wanted to further investigate the prevalence of coronary microvascular dysfunction, as assessed by coronary flow reserve (CFR), in a large cohort of patients with severe psoriasis and its association with psoriasis severity and duration, as well as other patient characteristics. Patients with a reduced CFR underwent angio-CT to exclude a stenosis of the coronary arteries, and no patients showed coronary artery disease. Therefore, all patients with an impaired CFR in our cohort were affected by coronary microvascular dysfunction.”

The study revealed that psoriasis severity, assessed by the Psoriasis Area Severity Index (PASI) score, and the duration of the disease were independently associated with lower CFR, along with the presence of psoriatic arthritis. Furthermore, results from the study showed that conventional cardiovascular risk factors, such as tobacco use, hyperlipidemia, and diabetes mellitus, were not independently associated with reduced CFR in patients with severe psoriasis. These findings emphasize the importance of considering inflammation and psoriasis-related factors in assessing cardiovascular risk in patients with severe psoriasis.

The findings shed light on the potential mechanism by which psoriasis increases the risk of cardiovascular complications in affected individuals, in agreement with previous studies on chronic inflammatory conditions, such as rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. The study supports the role of systemic inflammation in the development of coronary microvascular dysfunction.

Dr. Piaserico commented, "We should diagnose and actively search for microvascular dysfunction in patients with psoriasis, as this population is at particularly high risk. We might hypothesize that an early and effective treatment of psoriasis would restore the dysfunction and eventually prevent the future risk of myocardial infarction and heart failure associated with it. In keeping with this, some preliminary studies showed that coronary microvascular dysfunction is restored after a treatment with biologics. Nevertheless, prospective studies are needed to confirm whether these findings translate into reductions in cardiovascular events."

---

Notes for editors

The article is “Coronary Microvascular Dysfunction in Asymptomatic Patients with Severe Psoriasis,” by Stefano Piaserico, Evangelia Papadavid, Annagrazia Cecere, Gloria Orlando, Konstantrinos Theodoropoulos, Pelagia Katsimbri, George Makavos, Penelope Rafouli-Stergiou, Sabino Iliceto, Mauro Alaibac, Francesco Tona, and Ignatios Ikonomidis (https://doi.org/10.1016/j.jid.2023.02.037 opens in new tab/window). It appears online in advance of the Journal of Investigative Dermatology, volume 143, issue 10(October 2023), published by Elsevier.

The article is openly available for 30 days at https://www.jidonline.org/article/S0022-202X(23)01955-3/fulltext opens in new tab/window.

The full text of the article is also available to credentialed journalists upon request; contact Theresa Monturano at +1 215 239 3711 or [email protected] opens in new tab/window. Journalists wishing to interview the authors should contact Stefano Piaserico, MD, PhD, at [email protected] opens in new tab/window.

About Journal of Investigative Dermatology

The Journal of Investigative Dermatology opens in new tab/window (JID) is the official journal of the Society of Investigative Dermatology and the European Society for Dermatological Research. JID publishes high impact reports describing original research related to all aspects of cutaneous biology and skin diseases. Descriptions of important findings that result from basic, translational, or clinical research are published. Clinical research can include, but is not limited to, interventional trials, genetics studies, epidemiology, and health services research. www.jidonline.org opens in new tab/window

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.